Tissue Regenix Group PLC DermaPure® secures first GPO contract in US (9007C)
July 01 2016 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 9007C
Tissue Regenix Group PLC
01 July 2016
Tissue Regenix Group plc
DermaPure(R) secures first GPO contract in US
York, 1 July 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that Tissue Regenix Wound Care, Inc. has secured a
contract agreement with a national US Group Purchasing Organization
(GPO) for the use of DermaPure(R).
A GPO negotiates contracts and pricing with an Integrated
Delivery Network (IDN) on behalf of its members which can include;
regional alliances, hospitals and individual physician offices.
Effective from today, Tissue Regenix Wound Care Inc. secured a
3-year contract agreement with a national GPO which spans across 43
states and is affiliated with 48 IDNs, with a membership comprised
of more than 800 acute care hospitals, 186 different Health Systems
and more than 1000 long-term care facilities. This agreement now
makes it easier for physicians within these facilities to access
DermaPure(R) for the treatment of their patients.
Greg Bila, President Tissue Regenix Wound Care, Inc. commented:
'This first GPO agreement marks another significant milestone for
DermaPure(R), allowing a multitude of care settings and physicians
to access the product. The results and clinical support that we
have seen, to date, has been outstanding and we are pleased to be
able to convert this into further market penetration and
availability.'
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Officer
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTSDEEFSFMSEFM
(END) Dow Jones Newswires
July 01, 2016 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024